-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol Myers Squibb (BMY) Gets A Camzyos Boost, Is The Pipeline Optimism Already Priced In?

Simply Wall St·11/18/2026 00:18:48
Listen to the news

Bristol-Myers Squibb (BMY) is back on traders’ radar after fresh technical strength intersected with new clinical data for Camzyos in pediatric obstructive hypertrophic cardiomyopathy, increasing attention on the company’s broader biopharma pipeline.

Short term, momentum has cooled a bit, with the share price down 2.5% over the past day and 2.3% over the week. However, a 2.7% 1 month share price gain and 14.8% year to date share price return suggest the broader trend is still positive. Against that backdrop and the recent Camzyos update, Bristol-Myers Squibb’s 36.2% 1 year total shareholder return hints that investors have already started to reprice the pipeline and risk profile, even as traders now reassess how much of that optimism is already in the stock at about US$61 a share.

Scan beyond Bristol-Myers Squibb to see which other biopharma names are flashing similar pipeline and momentum signals using our curated 18 high quality undiscovered gems.

Bulls point to Bristol-Myers Squibb’s pipeline, Camzyos data and valuation gap, while bears flag falling revenue and profit. Which story does the current price around US$61 actually reflect as you look at the multiples today?

Most Popular Narrative: 115% Overvalued

The most followed narrative on Bristol-Myers Squibb pegs fair value at $28.50, far below the last close at $61.35. This frames the recent rally as rich rather than cheap according to TradingClimbers, an investor in the Simply Wall St Community who wrote the narrative.

Price sits slightly above my fair value estimate, so the stock looks fairly priced rather than cheap. The yield is attractive, but at this level the margin of safety is thin and the growth-adjusted picture is not supportive.

See why 1 investors see Bristol-Myers Squibb as 115% overvalued.

Result: Fair Value of $28.50 (OVERVALUED)

Still, patent expiries on older blockbusters and recent annual declines in revenue and net income could quickly challenge a claim that Bristol-Myers Squibb is overvalued.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Another View: Multiples Point To Value Support

While the community narrative tags Bristol-Myers Squibb as 115% overvalued at a fair value of $28.50, the market’s own yardsticks tell a different story. At a P/E of 13.6x, the stock trades well below the US Pharmaceuticals industry on 17.1x and a fair ratio of 24.4x, which suggests sentiment may already price in a lot of risk. The real question is whether this gap reflects a genuine cushion or signals that earnings expectations still need to catch up.

For a closer look at what the numbers imply about valuation pressure and room for error, See what the numbers say about this price — find out in our valuation breakdown..

NYSE:BMY P/E Ratio as at Nov 2026
NYSE:BMY P/E Ratio as at Nov 2026

Next Steps

If the mixed signals around Bristol-Myers Squibb leave you torn between caution and optimism, consider acting while sentiment is still split and test the numbers yourself. Start with the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Bristol-Myers Squibb?

Do not stop with Bristol-Myers Squibb when the broader market is full of fresh setups. Diversify your watchlist and stress test your thinking across different themes.